Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Scientists identify potent and selective IDE inhibitors with a new mode of action

June 21, 2010

Japanese researchers discover novel ACAT-2 inhibitors

June 21, 2010

Phase IIa trial of NU-1618 in hyperuricemia meets primary endpoint

June 18, 2010

Abbott and Neurocrine join to develop elagolix for endometriosis

June 18, 2010

Amylin, Lilly and Alkermes report on DURATION-4 trial of Bydureon

June 16, 2010

EMA's COMP recommends orphan status for DR Cysteamine in cystinosis

June 16, 2010

FDA clears phase I/II alpha-1-antitrypsin trial in type 1 diabetes

June 16, 2010

Chiasma reports on phase I trial of oral octreotide acetate

June 16, 2010

Boehringer Ingelheim discovers new 5-HT2C receptor agonists

June 16, 2010

Agile Therapeutics secures funds to advance AG-200-15 and AG-1000

June 15, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...